An Extension Study of CACZ885N2301, Multi-center, Open Label Study of Canakinumab in Japanese Patients With Periodic Fever Syndromes (TRAPS, HIDS, or crFMF)
Phase of Trial: Phase III
Latest Information Update: 30 May 2017
At a glance
- Drugs Canakinumab (Primary)
- Indications Hereditary autoinflammatory diseases
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 04 May 2017 Status changed from active, no longer recruiting to completed.
- 13 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2016 New trial record